The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Feb. 06, 2024
Filed:
Aug. 23, 2018
Applicant:
Cellact Pharma Gmbh, Dortmund, DE;
Inventor:
Nalan Utku, Munich, DE;
Assignee:
CELLACT PHARMA GMBH, Dortmund, DE;
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
G01N 31/00 (2006.01); G01N 33/53 (2006.01); G01N 33/574 (2006.01); A61K 31/7048 (2006.01); C12Q 1/6886 (2018.01);
U.S. Cl.
CPC ...
G01N 33/57438 (2013.01); A61K 31/7048 (2013.01); C12Q 1/6886 (2013.01); G01N 33/57407 (2013.01); G01N 33/57419 (2013.01); C12Q 2600/106 (2013.01); C12Q 2600/158 (2013.01); G01N 2333/918 (2013.01); G01N 2800/52 (2013.01);
Abstract
The present invention pertains to a diagnostic and therapeutic method for assessing whether a patient is susceptible to the treatment of an ester-prodrug. The methods of the invention include the analysis of carboxyelesterase 2 (CES2)-expression in tumor samples as a predictive value for the assessment of treatment success with an ester-prodrug of a chemotherapeutic agent. Alternatively, the invention provides methods involving the analysis of the urinary ratio of the prodrug and the active therapeutic as another predictive value for assessing treatment susceptibility.